Overview

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

Status:
Not yet recruiting
Trial end date:
2022-12-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2202 and co-administration of each component in fed condition in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited